Quantcast

Latest ARYx Therapeutics Stories

2008-11-04 09:00:30

ARYx Therapeutics, a biopharmaceutical company, has completed enrollment in EmbraceAC, a Phase II/III double-blind clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin. The purpose of the trial is to evaluate whether ATI-5923 is superior to warfarin in its ability to maintain patients within a target therapeutic range of the level of anticoagulation as measured by international normalized ratio (INR). Based upon recent...

2008-08-29 12:01:17

ARYx Therapeutics, a biopharmaceutical company focused on developing a portfolio of potentially safer oral drugs, has appointed David Beier to its board of directors. Mr Beier is a veteran of the biotechnology industry and has been instrumental in the development of US public policy impacting biotechnology companies, having served in both the industry and the Bill Clinton administration. Mr Beier is currently senior vice president of global government and corporate affairs for Amgen and...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related